Bifeprunox

In today's world, Bifeprunox has become a topic of great interest and relevance. The popularity of Bifeprunox has been increasing in recent years, generating a great impact in various areas. Both on a personal and professional level, Bifeprunox has taken center stage and has generated a great debate in society. This article aims to thoroughly analyze the phenomenon of Bifeprunox, exploring its various facets and its influence on different aspects of daily life. Through this analysis, we seek to shed light on Bifeprunox and offer a broad and objective vision that can help better understand its importance and impact on our current society.

Bifeprunox
Clinical data
ATC code
  • none
Identifiers
  • 7--1,3-benzoxazol-2(3H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H23N3O2
Molar mass385.467 g·mol−1
3D model (JSmol)
  • O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
  • InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) checkY
  • Key:CYGODHVAJQTCBG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects. An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007. In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

References

  1. ^ Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). "Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities". J. Med. Chem. 50 (4): 865–76. doi:10.1021/jm061180b. PMID 17300168.
  2. ^ "Bifeprunox". go.drugbank.com. Retrieved 2023-11-16.
  3. ^ Casey DE, Sands EE, Heisterberg J, Yang HM (October 2008). "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study". Psychopharmacology. 200 (3): 317–31. doi:10.1007/s00213-008-1207-7. PMID 18597078. S2CID 23291727.
  4. ^ Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
  5. ^ Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Archived 2011-07-14 at the Wayback Machine Lundbeck Press Release.
Wikious
Boobota
Sagapedia